The impact of Oncotype DX testing on breast cancer management and chemotherapy prescribing patterns in a tertiary referral centre

INTRODUCTION: The use of chemotherapy in node-negative, (O)Estrogen Receptor (ER)-positive breast cancer has changed significantly since the introduction of Oncotype DX to determine systemic recurrence risk based on tumour genomic signature. AIMS: This study aims to: 1. Document longitudinal changes...

Descripción completa

Detalles Bibliográficos
Autores principales: McVeigh, Terri Patricia, Hughes, Lauren M., Miller, Nicola, Sheehan, Margaret, Keane, Maccon, Sweeney, Karl J., Kerin, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science Ltd 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4204201/
https://www.ncbi.nlm.nih.gov/pubmed/25240289
http://dx.doi.org/10.1016/j.ejca.2014.08.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4204201/
https://www.ncbi.nlm.nih.gov/pubmed/25240289
http://dx.doi.org/10.1016/j.ejca.2014.08.002

Ejemplares similares